NasdaqCM:CEMI

Stock Analysis Report

Executive Summary

Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases.

Snowflake

Fundamentals

Mediocre balance sheet and overvalued.


Similar Companies

Share Price & News

How has Chembio Diagnostics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-0.5%

CEMI

-0.4%

US Medical Equipment

1.0%

US Market


1 Year Return

-43.6%

CEMI

12.8%

US Medical Equipment

6.7%

US Market

Return vs Industry: CEMI underperformed the US Medical Equipment industry which returned 12.8% over the past year.

Return vs Market: CEMI underperformed the US Market which returned 6.7% over the past year.


Share holder returns

CEMIIndustryMarket
7 Day-0.5%-0.4%1.0%
30 Day-17.2%-2.7%-1.8%
90 Day-5.6%-0.4%-1.8%
1 Year-43.6%-43.6%13.7%12.8%9.1%6.7%
3 Year-21.4%-21.4%70.0%64.8%46.0%36.6%
5 Year44.9%44.9%130.9%105.1%66.9%48.6%

Price Volatility Vs. Market

How volatile is Chembio Diagnostics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Chembio Diagnostics undervalued based on future cash flows and its price relative to the stock market?

3.49x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Undervalued: Insufficient data to calculate CEMI's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate CEMI's fair value to establish if it is undervalued.


Price Based on Earnings

PE vs Industry: CEMI is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: CEMI is unprofitable, so we can't compare its PE Ratio to the US market.


Price Based on Expected Growth

Low PEG Ratio: Insufficient data to calculate CEMI's PEG Ratio to determine if it is good value.


Price Based on Value of Assets

PB vs Industry: CEMI is good value based on its PB Ratio (3.5x) compared to the US Medical Equipment industry average (3.7x).


Next Steps

Future Growth

How is Chembio Diagnostics expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

77.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Earnings vs Savings Rate: CEMI is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CEMI is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CEMI is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CEMI's revenue (17.2% per year) is forecast to grow faster than the US market (7.3% per year).

High Growth Revenue: CEMI's revenue (17.2% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Estimates


Future Return on Equity

High Future ROE: Insufficient data to determine if CEMI's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Chembio Diagnostics performed over the past 5 years?

-29.6%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: CEMI is unprofitable, and losses have increased over the past 5 years at a rate of -29.6% per year.

Accelerating Growth: Unable to compare CEMI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CEMI is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (28.2%).


Return on Equity

High ROE: CEMI has a negative Return on Equity (-41.12%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: CEMI is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: CEMI is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Chembio Diagnostics's financial position?


Financial Position Analysis

Short Term Liabilities: CEMI's short term assets ($21.9M) exceeds its short term liabilities ($6.5M)

Long Term Liabilities: CEMI's short term assets ($21.9M) exceeds its long term liabilities ($7.6M)


Debt to Equity History and Analysis

Debt Level: CEMI's debt to equity ratio (1%) is considered satisfactory

Reducing Debt: Insufficient data to determine if CEMI's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: CEMI has a high level of physical assets or inventory.

Debt Coverage by Assets: CEMI's debt is covered by short term assets (assets are 76.139050x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CEMI has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: CEMI has less than a year of cash runway if free cash flow continues to reduce at historical rates of -49.7% each year


Next Steps

Dividend

What is Chembio Diagnostics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage0.8%forecastin3Yearsn/a

Current dividend yield vs market & industry


Dividend Yield and Payments Analysis

Notable Dividend: Unable to evaluate CEMI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate CEMI's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if CEMI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CEMI's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CEMI's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Chembio Diagnostics's salary, the management and board of directors tenure and is there insider trading?

2.9yrs

Average management tenure


CEO

John Sperzel (55yo)

5.6yrs

Tenure

US$1,456,097

Compensation

Mr. John J. Sperzel, III, B.Sc., has been the Chief Executive Officer and President of Chembio Diagnostics, Inc. since March 13, 2014. Mr. Sperzel is on leave of Absence on May 30, 2017. Mr. Sperzel served ...


CEO Compensation Analysis

Compensation vs. Market: John's total compensation ($USD1.46M) is about average for companies of similar size in the US market ($USD495.80K).

Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

2.9yrs

Average Tenure

55yo

Average Age

Experienced Management: CEMI's management team is considered experienced (2.9 years average tenure).


Board Age and Tenure

2.3yrs

Average Tenure

63yo

Average Age

Experienced Board: CEMI's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

SellUS$214,43424 May 19
Javan Esfandiari
EntityIndividual
Role
Chief Technology Officer
Chief Science & Technology Officer and Executive VP
Shares30,000
Max PriceUS$7.41
BuyUS$116,15016 Nov 18
John Potthoff
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares20,000
Max PriceUS$5.81
BuyUS$101,25006 Nov 18
Robert Passas
EntityIndividual
Role
Senior Key Executive
Senior VP & Chief Commercial Officer
Shares15,000
Max PriceUS$6.75

Ownership Breakdown


Management Team

  • David Gyorke (59yo)

    Senior VP & COO

    • Tenure: 2.8yrs
  • John Sperzel (55yo)

    President

    • Tenure: 5.6yrs
    • Compensation: US$1.46m
  • Javan Esfandiari (52yo)

    Chief Science & Technology Officer and Executive VP

    • Tenure: 15.8yrs
    • Compensation: US$812.65k
  • Konstantin Lyashchenko

    Research Director of Chembio Diagnostic Systems Inc

    • Tenure: 0yrs
    • Compensation: US$106.37k
  • Robert Passas (65yo)

    Senior VP & Chief Commercial Officer

    • Tenure: 3yrs
    • Compensation: US$271.10k
  • Neil Goldman (51yo)

    Executive VP & CFO

    • Tenure: 1.8yrs
    • Compensation: US$647.40k
  • Christine Rousseau

    Vice President of Corporate Development

    • Tenure: 1.3yrs

Board Members

  • Mary Polan (75yo)

    Independent Director

    • Tenure: 1.2yrs
    • Compensation: US$207.58k
  • Gail Page (64yo)

    Independent Director

    • Tenure: 2.3yrs
    • Compensation: US$25.00k
  • John Sperzel (55yo)

    President

    • Tenure: 5.6yrs
    • Compensation: US$1.46m
  • John Potthoff (51yo)

    Independent Director

    • Tenure: 1.4yrs
    • Compensation: US$167.55k
  • Kathy Davis (63yo)

    Chair of the Board

    • Tenure: 5.6yrs
    • Compensation: US$75.00k

Company Information

Chembio Diagnostics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Chembio Diagnostics, Inc.
  • Ticker: CEMI
  • Exchange: NasdaqCM
  • Founded: 1985
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: US$97.489m
  • Shares outstanding: 17.57m
  • Website: https://chembio.com

Number of Employees


Location

  • Chembio Diagnostics, Inc.
  • 555 Wireless Boulevard
  • Hauppauge
  • New York
  • 11788
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CEMINasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDOct 2000
D9IABST (Boerse-Stuttgart)YesCommon StockDEEUROct 2000

Biography

Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers t ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/14 01:47
End of Day Share Price2019/10/11 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

© 2018 SIMPLY WALL STREET PTY LTD, COMMUNITY DESIGN 2845206, US DESIGN PATENT #29/544/281, EUROPEAN DESIGN REGISTRATION #2845206, STANDARD & POOR’S FINANCIAL SERVICES LLC. ALL RIGHTS RESERVED.

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Copyright © 2018, Standard & Poor’s Financial Services LLC. Reproduction of S&P Capital IQ in any form is prohibited except with the prior written permission of S&P. S&P does not guarantee the accuracy, adequacy, completeness or availability of any information and is not responsible for any errors or omissions, regardless of the cause or for the results obtained from the use of such information. S&P DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall S&P be liable for any direct, indirect, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or lost profit and opportunity costs) in connection with subscriber’s or others’ use of S&P Capital IQ. (2018)